BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Krasinskas AM. Cholangiocarcinoma. Surgical Pathology Clinics 2018;11:403-29. [DOI: 10.1016/j.path.2018.02.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou B, Yang F, Qin L, Kuai J, Yang L, Zhang L, Sun P, Li G, Wang X. Computational study on novel natural compound inhibitor targeting IDH1_R132H. Aging (Albany NY) 2022;14. [PMID: 35802554 DOI: 10.18632/aging.204162] [Reference Citation Analysis]
2 Neumann O, Burn TC, Allgäuer M, Ball M, Kirchner M, Albrecht T, Volckmar A, Beck S, Endris V, Goldschmid H, Lehmann U, Seker-cin H, Uhrig S, Roessler S, Budczies J, Fröhling S, Longerich T, Wagner AH, Vogel A, Schirmacher P, Stenzinger A, Kazdal D. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing. Br J Cancer. [DOI: 10.1038/s41416-022-01908-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Vij M, Puri Y, Rammohan A, G G, Rajalingam R, Kaliamoorthy I, Rela M. Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review. World J Gastrointest Oncol 2022; 14(3): 607-627 [DOI: 10.4251/wjgo.v14.i3.607] [Reference Citation Analysis]
4 Ware MB, Zaidi MY, Yang J, Turgeon MK, Krasinskas A, Mace TA, Keenan K, Farren MR, Ruggieri AN, Li Y, Zhang C, Chen Z, Young GS, Elnaggar O, Che Z, Maithel SK, Bekaii-saab T, El-rayes B, Lesinski GB. Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. Br J Cancer 2020;123:1377-86. [DOI: 10.1038/s41416-020-1018-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jingdong L, Yongfu X, Yang G, Jian X, Xujian H, Jianhua L, Wenxing Z, Renyi Q, Xinming Y, Shuguo Z, Xiao L, Bin P, Qifan Z, Dewei L, Zhao-Hui T. Minimally invasive surgery for hilar cholangiocarcinoma: a multicenter retrospective analysis of 158 patients. Surg Endosc 2020. [PMID: 33258033 DOI: 10.1007/s00464-020-08161-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol 2021;32:1111-26. [PMID: 33932504 DOI: 10.1016/j.annonc.2021.04.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Safarpour AR, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh F, Shamsaeefar A, Niknam R, Sivandzadeh GR, Lankarani KB, Ejtehadi F. Cholangiocarcinoma and liver transplantation: What we know so far? World J Gastrointest Pathophysiol 2021; 12(5): 84-105 [PMID: 34676129 DOI: 10.4291/wjgp.v12.i5.84] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gao Z, Wang J, Shen S, Bo X, Suo T, Ni X, Liu H, Huang L, Liu H. The impact of preoperative biliary drainage on postoperative outcomes in patients with malignant obstructive jaundice: a retrospective analysis of 290 consecutive cases at a single medical center. World J Surg Oncol 2022;20:7. [PMID: 34991594 DOI: 10.1186/s12957-021-02476-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sun Q, Wang H, Xiao B, Xue D, Wang G. Development and Validation of a 6-Gene Hypoxia-Related Prognostic Signature For Cholangiocarcinoma. Front Oncol 2022;12:954366. [DOI: 10.3389/fonc.2022.954366] [Reference Citation Analysis]
10 Zheng YW, Miao XY, Xiong L, Chen B, Kong FH, Zhou JJ, Liu ZT, Wen Y, Zhang ZJ, Zou H. Sulfasalazine Sensitizes Polyhematoporphyrin-Mediated Photodynamic Therapy in Cholangiocarcinoma by Targeting xCT. Front Pharmacol 2021;12:723488. [PMID: 34483935 DOI: 10.3389/fphar.2021.723488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kanber Y, Pusztaszeri M, Auger M. Immunocytochemistry for diagnostic cytopathology-A practical guide. Cytopathology 2021;32:562-87. [PMID: 34033162 DOI: 10.1111/cyt.12993] [Reference Citation Analysis]
12 Idrees JJ, Merath K, Gani F, Bagante F, Mehta R, Beal E, Cloyd JM, Pawlik TM. Trends in centralization of surgical care and compliance with National Cancer Center Network guidelines for resected cholangiocarcinoma. HPB 2019;21:981-9. [DOI: 10.1016/j.hpb.2018.11.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
13 Wu Z, Liu R, Miao X, Li D, Zou Q, Yuan Y, Yang Z. Prognostic and clinicopathological significance of Hapto and Gremlin1 expression in extrahepatic cholangiocarcinoma. J Cancer 2020;11:199-207. [PMID: 31892986 DOI: 10.7150/jca.36886] [Reference Citation Analysis]
14 Zhu B, Qian W, Han C, Bai T, Hou X. Piezo 1 activation facilitates cholangiocarcinoma metastasis via Hippo/YAP signaling axis. Mol Ther Nucleic Acids 2021;24:241-52. [PMID: 33767919 DOI: 10.1016/j.omtn.2021.02.026] [Reference Citation Analysis]
15 Pastore M, Lori G, Gentilini A, Taddei ML, Di Maira G, Campani C, Recalcati S, Invernizzi P, Marra F, Raggi C. Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. Cells 2020;9:E596. [PMID: 32138158 DOI: 10.3390/cells9030596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Xu X, Chen D, Feng X, Hu J, Ge J, Yan C, Zhang D, Ling Z, Chen J, Wu J. Apolipoprotein B Is Associated With the Microenvironment of Cholangiocarcinoma. Front Oncol 2021;11:654689. [PMID: 33954113 DOI: 10.3389/fonc.2021.654689] [Reference Citation Analysis]
17 Matsukuma KE, Yeh MM. Update on the pathology of liver neoplasms. Ann Diagn Pathol. 2019;38:126-137. [PMID: 30597357 DOI: 10.1016/j.anndiagpath.2018.10.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39 Suppl 1:7-18. [PMID: 30882996 DOI: 10.1111/liv.14093] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 33.5] [Reference Citation Analysis]
19 Wu L, Yang J, Liu Y, Hong Z, Guo P, Feng L, Ke RS, Li Z. Impact of lncRNA SOX9-AS1 overexpression on the prognosis and progression of intrahepatic cholangiocarcinoma. Clin Res Hepatol Gastroenterol 2022;:101999. [PMID: 35870795 DOI: 10.1016/j.clinre.2022.101999] [Reference Citation Analysis]
20 Mettman D, Saeed A, Shold J, Laury R, Ly A, Khan I, Golem S, Olyaee M, O'Neil M. Refined pancreatobiliary UroVysion criteria and an approach for further optimization. Cancer Med 2021. [PMID: 34374212 DOI: 10.1002/cam4.4043] [Reference Citation Analysis]
21 Chen D, Wu H, Feng X, Chen Y, Lv Z, Kota VG, Chen J, Wu W, Lu Y, Liu H, Zhang Y, Zheng S, Wu J. DNA Methylation of Cannabinoid Receptor Interacting Protein 1 Promotes Pathogenesis of Intrahepatic Cholangiocarcinoma Through Suppressing Parkin-Dependent Pyruvate Kinase M2 Ubiquitination. Hepatology 2021;73:1816-35. [PMID: 32955740 DOI: 10.1002/hep.31561] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
22 Chamberlain CX, Faust E, Goldschmidt D, Webster N, Boscoe AN, Macaulay D, Peters ML. Burden of illness for patients with cholangiocarcinoma in the United States: a retrospective claims analysis. J Gastrointest Oncol 2021;12:658-68. [PMID: 34012657 DOI: 10.21037/jgo-20-544] [Reference Citation Analysis]
23 Deenonpoe R, Sa-Ngiamwibool P, Watcharadetwittaya S, Thanee M, Intuyod K, Kongpan T, Padthaisong S, Nutalai R, Chamgramol Y, Pairojkul C. Fluorescence in situ hybridization detection of chromosome 7 and/or 17 polysomy as a prognostic marker for cholangiocarcinoma. Sci Rep 2022;12:8441. [PMID: 35589822 DOI: 10.1038/s41598-022-11945-8] [Reference Citation Analysis]
24 Kim JH, Yoon JH, Joo I, Lee JM. Evaluation of Primary Liver Cancers Using Hepatocyte-Specific Contrast-Enhanced MRI: Pitfalls and Potential Tips. J Magn Reson Imaging 2021;53:655-75. [PMID: 32700807 DOI: 10.1002/jmri.27213] [Reference Citation Analysis]
25 Li BB, Lu SL, He X, Lei B, Yao JN, Feng SC, Yu SP. Da Vinci robot-assisted pancreato-duodenectomy in a patient with situs inversus totalis: A case report and review of literature. World J Gastrointest Oncol 2022; 14(7): 1363-1371 [DOI: 10.4251/wjgo.v14.i7.1363] [Reference Citation Analysis]
26 Avadhani V, Cohen C, Siddiqui MT, Krasinskas A. A Subset of Intrahepatic Cholangiocarcinomas Express Albumin RNA as Detected by In Situ Hybridization. Appl Immunohistochem Mol Morphol 2021;29:175-9. [PMID: 33181516 DOI: 10.1097/PAI.0000000000000882] [Reference Citation Analysis]
27 Wang J, Yang Z, Luo M, Xu C, Du M, Liu Y. Value of Intravoxel Incoherent Motion (IVIM) Imaging for Differentiation between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Contrast Media Mol Imaging 2022;2022:1504463. [PMID: 35615729 DOI: 10.1155/2022/1504463] [Reference Citation Analysis]
28 Carotenuto M, Sacco A, Forgione L, Normanno N. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2022.00079] [Reference Citation Analysis]
29 Kankeu Fonkoua LA, Serrano Uson Junior PL, Mody K, Mahipal A, Borad MJ, Roberts LR. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opin Ther Targets 2022. [PMID: 35034558 DOI: 10.1080/14728222.2022.2029412] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Zhuang L, Meng Z, Yang Z. MRPL27 contributes to unfavorable overall survival and disease-free survival from cholangiocarcinoma patients. Int J Med Sci 2021;18:936-43. [PMID: 33456351 DOI: 10.7150/ijms.50782] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Ni JY, An C, Zhang TQ, Huang ZM, Jiang XY, Huang JH. Predictive value of the albumin-bilirubin grade on long-term outcomes of CT-guided percutaneous microwave ablation in intrahepatic cholangiocarcinoma. Int J Hyperthermia 2019;36:328-36. [PMID: 30689465 DOI: 10.1080/02656736.2019.1567834] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
32 Li J, Xiong Y, Yang G, Zhang L, Riaz M, Xu J, Li Q, Tang Z. Complete laparoscopic radical resection of hilar cholangiocarcinoma: technical aspects and long-term results from a single center. Wideochir Inne Tech Maloinwazyjne 2021;16:62-75. [PMID: 33786118 DOI: 10.5114/wiitm.2020.97363] [Reference Citation Analysis]
33 Sun HB, Zhang GC, Liu J, Nie CS. Long noncoding RNA LINC00184 facilitates the proliferation, metastasis, and adenine metabolism of cholangiocarcinoma via modulating hsa-miR-23b-3p/ANXA2 axis. Environ Toxicol 2021;36:1576-90. [PMID: 33913242 DOI: 10.1002/tox.23154] [Reference Citation Analysis]
34 Guedj N, Blaise L, Cauchy F, Albuquerque M, Soubrane O, Paradis V. Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma. Mod Pathol 2021;34:408-16. [PMID: 32860001 DOI: 10.1038/s41379-020-00656-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Wang Q, Xu Y, Wang SM, Hu AY, Pan YC, Zhang SH. Histopathological evidence of intrahepatic cholangiocarcinoma occurring in ductal plate malformation: A clinicopathologic study of 5 cases. Ann Diagn Pathol 2021;55:151828. [PMID: 34571341 DOI: 10.1016/j.anndiagpath.2021.151828] [Reference Citation Analysis]
36 Cigliano A, Chen X, Calvisi DF. Current challenges to underpinning the genetic basis for cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:511-26. [PMID: 33888034 DOI: 10.1080/17474124.2021.1915128] [Reference Citation Analysis]
37 Barner-Rasmussen N, Pukkala E, Hadkhale K, Färkkilä M. Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. United European Gastroenterol J 2021. [PMID: 34533900 DOI: 10.1002/ueg2.12154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Jia X, Lu S, Zeng Z, Liu Q, Dong Z, Chen Y, Zhu Z, Hong Z, Zhang T, Du G, Xiang J, Wu D, Bai W, Yang B, Li Y, Huang J, Li H, Safadi R, Lu Y. Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma. Hepatology 2020;71:893-906. [PMID: 31298745 DOI: 10.1002/hep.30852] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 22.5] [Reference Citation Analysis]
39 Xiong F, Gong J, Wang Q. Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report. Onco Targets Ther 2020;13:6385-91. [PMID: 32753881 DOI: 10.2147/OTT.S250454] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Zheng BH, Zhang C, Wan WZ, Sun WT, Cheng X, Ni XJ, Ni XL, Suo T, Liu H, Shen S, Liu HB. The clinical and prognostic factors for biliary neuroendocrine neoplasm: a study based on the SEER database. BMC Surg 2022;22:253. [PMID: 35768809 DOI: 10.1186/s12893-022-01689-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Ahn KS, Kang KJ. Molecular heterogeneity in intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12(12): 1148-1157 [PMID: 33442444 DOI: 10.4254/wjh.v12.i12.1148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
42 Wu L, Merath K, Farooq A, Hyer JM, Tsilimigras DI, Paredes AZ, Mehta R, Sahara K, Shen F, Pawlik TM. Photodynamic therapy may provide a benefit over systemic chemotherapy among non-surgically managed patients with extrahepatic cholangiocarcinoma. J Surg Oncol 2019. [PMID: 31742706 DOI: 10.1002/jso.25773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Li H, Qu L, Zhang H, Liu J, Zhang X. A comprehensive transcriptomic landscape of cholangiocarcinoma based on bioinformatics analysis from large cohort of patients. Sci Rep 2021;11:13713. [PMID: 34211100 DOI: 10.1038/s41598-021-93250-4] [Reference Citation Analysis]
44 Ainthachot S, Sa-ngiamwibool P, Thanee M, Watcharadetwittaya S, Chamgramol Y, Pairojkul C, Deenonpoe R. Chromosomal aberrations, visualized using UroVysion® fluorescence in-situ hybridization assay, can predict poor prognosis in formalin-fixed paraffin-embedded tissues of cholangiocarcinoma patients. Human Pathology 2022. [DOI: 10.1016/j.humpath.2022.05.008] [Reference Citation Analysis]
45 Rizzo A, Cusmai A, Palmiotti G. Second-line fluoropyrimidine-based doublet chemotherapy for advanced biliary tract cancer: a new standard of care? Expert Rev Gastroenterol Hepatol 2022;16:201-3. [PMID: 35220859 DOI: 10.1080/17474124.2022.2047652] [Reference Citation Analysis]
46 Lertpanprom M, Silsirivanit A, Tippayawat P, Proungvitaya T, Roytrakul S, Proungvitaya S. High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma. Front Public Health 2022;10:835914. [DOI: 10.3389/fpubh.2022.835914] [Reference Citation Analysis]
47 Liu Y, Yeh MM. Bile duct dysplasia and associated invasive carcinoma: clinicopathological features, diagnosis, and practical challenges. Hum Pathol 2022:S0046-8177(22)00157-5. [PMID: 35714833 DOI: 10.1016/j.humpath.2022.06.012] [Reference Citation Analysis]